A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

BBM-H901 was shown to significantly reduce bleeding rates among hemophilia B patients in clinical trials, a new study in China shows.

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

Objectives To investigate the efficacy and safety of subcutaneously (SC) administered tranexamic acid. Methods A retrospective chart review of the use of SC tranexamic acid in a single palliative care ...

Sanofi said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the country. The French pharmaceutical company ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China. Broadcom Reports Earnings After the Close Today. Analysts Expect Strong ...

PHILADELPHIA – More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an ...